Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

globenewswire.com
NERV The article announces the company's participation in a healthcare conference, which is a standard corporate event and does not inherently indicate positive or negative performance. It focuses on the logistics of the event and the company's general business focus.

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.

If you are interested in meeting with the Minerva team during the conference, please reach out to your Jefferies representative.

A replay of the presentation will be available on the Company's Investors & Media Events and Presentations webpage for ninety days following the event.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva’s goal is to transform the lives of patients with improved therapeutic options, including roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.

Contacts:

Frederick Ahlholm

Chief Financial Officer

Minerva Neurosciences, Inc.

FAhlholm@minervaneurosciences.com

Corey Davis, Ph.D.

LifeSci Advisors, LLC

212-915-2577

cdavis@lifesciadvisors.com